Corticotropin releasing factor 2 receptor agonist and use thereof
By developing a long-acting corticotropin-releasing factor 2 receptor agonist, the problems of short half-life and muscle loss associated with NBI-69734 were solved, resulting in higher patient compliance and improved muscle anabolism.
WO2026139062A1 Publication Date: 2026-07-02HANG ZHOU SCIWIND BIOSCIENCES CO LTD +1
7 Cites 0 Cited by
Patent Information
- Application Number
- PCT/CN2025/146155
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-12-26
- Filing Date
- 2025-12-26
- Publication Date
- 2026-07-02
AI Technical Summary
Technical Problem
The existing corticotropin-releasing factor 2 receptor agonist NBI-69734 has a short half-life, requires frequent intravenous injections, has poor patient compliance, and the muscle loss caused by GLP-1 drugs increases the risk of cardiovascular disease and osteoporosis.
Method used
A novel long-acting adrenocorticotropic hormone-releasing factor 2 receptor agonist has been developed, which contains a specific amino acid sequence and is modified with fatty acids to improve the agonist's half-life and selectivity and reduce the dosing frequency.
Benefits of technology
It prolongs the half-life of agonists, improves patient compliance, reduces muscle loss, lowers the risk of cardiovascular disease and osteoporosis, and enhances muscle anabolism.
✦ Generated by Eureka AI based on patent content.
Abstract
Provided are a corticotropin releasing factor 2 receptor agonist and use thereof. The corticotropin releasing factor 2 receptor agonist can be used for preventing and / or treating heart failure, hypertension, obesity, sarcopenia, diabetes, chronic kidney disease, and related diseases.
Need to check novelty before this filing date? Find Prior Art